2nd Quarter - Report

SAREPTA THERAPEUTICS, INC. for SAREPTA THERAPEUTICS, INC.

Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval

LobbyistCovered position, as disclosed
DIANE BERRY —
STACEY FRISK —
CAROLYN HICKEY —
KIP PAYNE New Senior Legislative Assistant, U.S. House of Representatives

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 7667 (117th), H.R. 7389 (117th), H.R. 8152 (117th), S. 4348 (117th)

Taxation/Internal Revenue Code TAX

Tax issues related to research and development

LobbyistCovered position, as disclosed
KIP PAYNE New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.